# SPDYE3, A Novel Cancer Testis (CT) Antigen for Glioma Immunotherapy

> **NIH NIH R03** · UNIVERSITY OF FLORIDA · 2022 · $76,250

## Abstract

PROJECT SUMMARY
 Gliomas are heterogeneous brain tumors with capacity for malignant propagation, and no treatment
options are curative. Our studies show that an uncharacteristic cancer testis antigen, SPDYE3 was found to
be overexpressed in all subtypes as well as low- and high-grade gliomas, and its expression is associated a
poor patient’s survival. Interestingly, SPDYE3 protein contains tandem repeat (TR) epitopes that have high
binding affinity to predominant HLA haplotypes (HLA-A*02, HLA-A*01 and HLA-B*07), which makes this
molecule a potential glioma target for TCR-based T cell therapy.
 In this proposed study, we will test our hypothesis that SPDYE3 is a novel glioma tumor antigen,
which is involved in tumor progression. We anticipate translating our preclinical findings from this
proposed study into a future clinical applications for patients with various stages of gliomas.

## Key facts

- **NIH application ID:** 10359481
- **Project number:** 1R03CA255820-01A1
- **Recipient organization:** UNIVERSITY OF FLORIDA
- **Principal Investigator:** Jianping Huang
- **Activity code:** R03 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $76,250
- **Award type:** 1
- **Project period:** 2022-04-21 → 2024-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10359481

## Citation

> US National Institutes of Health, RePORTER application 10359481, SPDYE3, A Novel Cancer Testis (CT) Antigen for Glioma Immunotherapy (1R03CA255820-01A1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10359481. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*